brodalumab

Brodalumab is a human monoclonal antibody used in the treatment of inflammatory skin diseases. It binds to the interleukin-17 receptor A (IL-17RA), blocking signaling from multiple IL-17 family cytokines such as IL-17A and IL-17F. By inhibiting this pathway, brodalumab reduces inflammation involved in plaque psoriasis and related conditions.

Clinical use is for adults with moderate-to-severe plaque psoriasis in regions where approved. It is administered by subcutaneous injection according to regulatory labeling and is often considered after conventional systemic therapies have failed or are unsuitable. In some regions, it has been studied for psoriatic arthritis and other inflammatory conditions but may not be approved for those indications.

Safety: Brodalumab carries a boxed warning for suicidality; patients are enrolled in a risk management program in the United States and other jurisdictions. Common adverse events include infections (notably candida), injection-site reactions, and headaches. Serious adverse effects may include neutropenia, inflammatory bowel disease, and psychiatric events; use requires careful assessment of psychiatric history. Contraindications or precautionary guidance address active psychiatric illness and certain infectious risks.

Development and regulatory status: Brodalumab was developed by AstraZeneca and has been approved in several regions for plaque psoriasis, with approvals and access varying by country and region. As with other IL-17 inhibitors, ongoing pharmacovigilance and postmarketing reporting monitor safety outcomes.